Welcome to our dedicated page for IRADIMED SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRADIMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRADIMED's regulatory disclosures and financial reporting.
IRADIMED Corporation insider activity centered on trust-held shares linked to its CEO. A trust associated with CEO, President and Chairman Roger E. Susi, the Phillip Susi 2008 Dynasty Trust, sold a total of 5,000 shares of IRADIMED common stock on January 5, 2026 in multiple transactions coded as open-market sales.
The reported weighted average sale prices ranged from $95.10 to $99.48, with underlying trade price ranges disclosed between $94.55 and $99.60, all under a Rule 10b5-1 trading plan adopted on June 16, 2025. After these sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 shares, while additional indirect holdings reported for Roger E. Susi were 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.
Iradimed Corp’s CEO, president, chairman and 10% owner Roger E. Susi reported insider sales of the company’s common stock. On 12/15/2025, a Rule 10b5-1 trading plan arranged for the sale of 4,269 shares at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13, both through the Phillip Susi 2008 Dynasty Trust.
After these transactions, the form reports indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust. The filing notes the trades were executed under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025, and that beneficial ownership of certain securities is disclaimed except to the extent of pecuniary interest.
Iradimed Corporation director Hilda Scharen-Guivel reported receiving 1,026 restricted stock units on December 11, 2025 under the company’s 2023 Equity Incentive Plan. The units were granted at a price of $0 and each restricted stock unit converts into one share of common stock.
The restricted stock units vest in two equal annual installments beginning on December 11, 2026, spreading the award over two years. After this grant, she beneficially owns 1,932 derivative securities, held directly.
Iradimed Corporation reported that one of its directors received an equity award of 1,026 restricted stock units (RSUs) on December 11, 2025 under the company’s 2023 Equity Incentive Plan. Each RSU converts into one share of common stock when it vests, so this grant represents the right to receive the same number of common shares in the future.
The RSUs vest in two equal annual installments beginning on December 11, 2026, aligning the director’s compensation with longer-term company performance. After this grant, the director beneficially owns 1,932 RSUs, all held as a direct ownership interest.
Iradimed Corporation director Monty K. Allen reported an equity award of derivative securities. On December 11, 2025, he received 1,026 restricted stock units (RSUs) under Iradimed Corporation's 2023 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal annual installments beginning on December 11, 2026, and upon each vesting date he will receive one share of common stock for each vested RSU. Following this grant, he beneficially owns 1,932 RSUs directly.
Iradimed Corporation reported an insider equity transaction by an officer serving as Chief Commercial Officer. On December 11, 2025, the officer converted 996 restricted stock units into common stock and disposed of 309 shares at $97.38 per share, resulting in 687 shares of common stock held directly afterward.
The restricted stock units were granted under Iradimed’s 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 11, 2025. Following this activity, the officer beneficially owned 1,994 restricted stock units in addition to the directly held common stock.
Iradimed Corporation director Hilda Scharen-Guivel reported acquiring 905 shares of common stock through the conversion of restricted stock units. The transaction on December 11, 2025 is coded "M", indicating an exercise or conversion of derivative securities, and increased her directly held common stock to 8,598 shares. A related entry in the derivative table shows 905 restricted stock units converting into 905 common shares at an exercise price of $0, leaving 906 restricted stock units beneficially owned. The restricted stock units were granted under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025, with shares of common stock delivered as each installment vests.
Iradimed Corporation reported an insider equity transaction by director James B. Hawkins. On December 11, 2025, 905 shares of common stock were acquired following the conversion of restricted stock units, at an exercise price of $0. After this transaction, Hawkins directly beneficially owns 29,647 shares of Iradimed common stock.
The derivative position involved 905 restricted stock units that converted into an equal number of common shares on a one-for-one basis. These units were originally granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025. Following the reported transaction, 906 restricted stock units remain beneficially owned.
Iradimed Corporation’s chief financial officer, John Glenn, reported several personal stock transactions in the company’s common shares on December 11, 2025. He sold 14,468 shares at a weighted average price of $97.26 in multiple trades and an additional 532 shares at $98.09, as part of his ongoing equity activity.
On the same date, 1,812 restricted stock units (RSUs) converted into common stock on a one‑for‑one basis, and 714 shares were withheld at $97.38 to cover tax obligations, leaving him with 8,460 shares of common stock held directly. He also beneficially owns 3,624 RSUs granted under Iradimed’s 2023 Equity Incentive Plan, which vest in three equal annual installments beginning on December 11, 2025.
Iradimed Corporation director Monty K. Allen reported converting 905 restricted stock units into shares of common stock on December 11, 2025, and now directly holds 22,000 shares.
The restricted stock units were granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 11, 2025; after this transaction, 906 restricted stock units remain, each convertible into one share of common stock upon vesting.